These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26503793)

  • 1. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.
    van der Ree MH; van der Meer AJ; van Nuenen AC; de Bruijne J; Ottosen S; Janssen HL; Kootstra NA; Reesink HW
    Aliment Pharmacol Ther; 2016 Jan; 43(1):102-13. PubMed ID: 26503793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
    van der Ree MH; van der Meer AJ; de Bruijne J; Maan R; van Vliet A; Welzel TM; Zeuzem S; Lawitz EJ; Rodriguez-Torres M; Kupcova V; Wiercinska-Drapalo A; Hodges MR; Janssen HL; Reesink HW
    Antiviral Res; 2014 Nov; 111():53-9. PubMed ID: 25218783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of HCV infection by targeting microRNA.
    Janssen HL; Reesink HW; Lawitz EJ; Zeuzem S; Rodriguez-Torres M; Patel K; van der Meer AJ; Patick AK; Chen A; Zhou Y; Persson R; King BD; Kauppinen S; Levin AA; Hodges MR
    N Engl J Med; 2013 May; 368(18):1685-94. PubMed ID: 23534542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
    Ottosen S; Parsley TB; Yang L; Zeh K; van Doorn LJ; van der Veer E; Raney AK; Hodges MR; Patick AK
    Antimicrob Agents Chemother; 2015 Jan; 59(1):599-608. PubMed ID: 25385103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
    van der Ree MH; de Vree JM; Stelma F; Willemse S; van der Valk M; Rietdijk S; Molenkamp R; Schinkel J; van Nuenen AC; Beuers U; Hadi S; Harbers M; van der Veer E; Liu K; Grundy J; Patick AK; Pavlicek A; Blem J; Huang M; Grint P; Neben S; Gibson NW; Kootstra NA; Reesink HW
    Lancet; 2017 Feb; 389(10070):709-717. PubMed ID: 28087069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection.
    Lee TH; Matta B; King BD; Hodges MR; Tillmann HL; Patel K
    J Med Virol; 2015 Oct; 87(10):1722-6. PubMed ID: 25963774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion.
    Goldaracena N; Spetzler VN; Echeverri J; Kaths JM; Cherepanov V; Persson R; Hodges MR; Janssen HL; Selzner N; Grant DR; Feld JJ; Selzner M
    Am J Transplant; 2017 Apr; 17(4):970-978. PubMed ID: 27805315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.
    Gebert LF; Rebhan MA; Crivelli SE; Denzler R; Stoffel M; Hall J
    Nucleic Acids Res; 2014 Jan; 42(1):609-21. PubMed ID: 24068553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen.
    Ninomiya M; Kondo Y; Kimura O; Funayama R; Nagashima T; Kogure T; Morosawa T; Tanaka Y; Nakayama K; Shimosegawa T
    J Viral Hepat; 2016 May; 23(5):330-9. PubMed ID: 26924666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.
    Hsi E; Huang CF; Dai CY; Juo SH; Chou WW; Huang JF; Yeh ML; Lin ZY; Chen SC; Wang LY; Chuang WL; Yu ML
    Antiviral Res; 2014 May; 105():135-42. PubMed ID: 24637254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum microRNA-122/222 levels are potential diagnostic biomarkers in Egyptian patients with chronic hepatitis C but not hepatic cancer.
    Motawi TM; Sadik NA; Shaker OG; Ghaleb MH
    Tumour Biol; 2016 Jul; 37(7):9865-74. PubMed ID: 26812693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global microRNA expression profiling in the liver biopsies of hepatitis B virus-infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injury.
    Singh AK; Rooge SB; Varshney A; Vasudevan M; Bhardwaj A; Venugopal SK; Trehanpati N; Kumar M; Geffers R; Kumar V; Sarin SK
    Hepatology; 2018 May; 67(5):1695-1709. PubMed ID: 29194684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV infection and miravirsen.
    Janssen HL; Kauppinen S; Hodges MR
    N Engl J Med; 2013 Aug; 369(9):878. PubMed ID: 23984739
    [No Abstract]   [Full Text] [Related]  

  • 14. HCV infection and miravirsen.
    Sanchez-Niño MD; Ortiz A
    N Engl J Med; 2013 Aug; 369(9):877-8. PubMed ID: 23984740
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release.
    El-Diwany R; Wasilewski LN; Witwer KW; Bailey JR; Page K; Ray SC; Cox AL; Thomas DL; Balagopal A
    J Virol; 2015 Sep; 89(18):9454-64. PubMed ID: 26157120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection.
    Peveling-Oberhag J; Crisman G; Schmidt A; Döring C; Lucioni M; Arcaini L; Rattotti S; Hartmann S; Piiper A; Hofmann WP; Paulli M; Küppers R; Zeuzem S; Hansmann ML
    Leukemia; 2012 Jul; 26(7):1654-62. PubMed ID: 22307176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roadmap of miR-122-related clinical application from bench to bedside.
    Qiu Z; Dai Y
    Expert Opin Investig Drugs; 2014 Mar; 23(3):347-55. PubMed ID: 24354366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.
    Köberle V; Waidmann O; Kronenberger B; Andrei A; Susser S; Füller C; Perner D; Zeuzem S; Sarrazin C; Piiper A
    J Viral Hepat; 2013 Aug; 20(8):530-5. PubMed ID: 23808991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
    Zhang S; Ouyang X; Jiang X; Gu D; Lin Y; Kong SK; Xie W
    Int J Med Sci; 2015; 12(7):590-8. PubMed ID: 26283876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-targeting therapeutics for hepatitis C.
    Baek J; Kang S; Min H
    Arch Pharm Res; 2014 Mar; 37(3):299-305. PubMed ID: 24385319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.